We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Bio Path Holdings Inc (BPTH) USD0.001

Sell:$5.04 Buy:$5.10 Change: $0.96 (29.63%)
Market closed |  Prices as at close on 18 April 2024 | Switch to live prices |
Sell:$5.04
Buy:$5.10
Change: $0.96 (29.63%)
Market closed |  Prices as at close on 18 April 2024 | Switch to live prices |
Sell:$5.04
Buy:$5.10
Change: $0.96 (29.63%)
Market closed |  Prices as at close on 18 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.

Contact details

Address:
4710 BELLAIRE BOULEVARD, SUITE 210
BELLAIRE
77401
United States
Telephone:
+1 (832) 7421357
Website:
https://www.biopathholdings.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BPTH
ISIN:
US09057N4097
Market cap:
$2.30 million
Shares in issue:
753,795
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Peter Nielsen
    Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer
  • Douglas Morris
    Director of Investor Relations, Secretary, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.